Heisoog Kim1,2, Ciprian Catana1,
Eva-Maria Ratai1, Wei-Ting Zhang1, Ovidiu C. Andronesi1,
Tracy T. Batcheolor3, Rakesh K. Jain4, Alma Gregory
Sorensen1
1A.A.Martinos center, Massachusetts
General Hospital, Charlestown, MA, United States; 2NSE/HST,
Massachusetts Institute of Technology, Cambridge, MA, United States; 3Neurology,
Massachusetts General Hospital, Boston, MA, United States; 4Radiology,
Massachusetts General Hospital, Boston, MA, United States
This
study investigated early changes in predominant metabolites for assessment of
tumor response to anti-angiogenic agents in rGBM using 1H-MRS. After one
dose, NAA/norCre in ET showed a significant increase in good-OS patients
(12/19) and no such increase in poor-OS. NAA/Cho increased in good-OS, while
decreasing in poor-OS. There were no
significant changes in norCre or MRI parameters, including T1, FLAIR, and
ADC. The change in NAA/norCre after one dose suggests a revival of neuronal
activity as well as a recovery of metabolite concentrations due to reduction
of edema. NAA/Cho changes also seem to
correlate well with overall survival.